We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Shenzhen New Industries Biomedical Engineering Co., Ltd. (SNIBE)

Shenzhen New Industries Biomedical Engineering Co., Ltd. (SNIBE) is a biotechnology company specializing in clinical ... read more Featured Products: More products

Download Mobile App

SNIBE Displays Super High Throughput CLIA Analyzer Powered by X Tech Technology

By LabMedica International staff writers
Posted on 21 May 2023
Print article
Image: The MAGLUMI X series CLIA analyzers is powered by X Tech technology (Photo courtesy of Snibe)
Image: The MAGLUMI X series CLIA analyzers is powered by X Tech technology (Photo courtesy of Snibe)

Snibe (Shenzhen, China) is showcasing its latest products with high-performance features at Euromedlab Roma 2023, including the newest member of its X-series of new-generation chemiluminescence immunoassay (CLIA) analyzers.

MAGLUMI X Tech is the core technology powering the X series of fully automatic CLIA analyzers which provide more efficient, convenient, and reliable immunology diagnostic solutions for laboratories and hospitals. The technology helps the X series analyzers deliver an amazing performance, higher accuracy, and further precision, while also making them affordable and easy to operate. The MAGLUMI X series offers three models to meet all types of demands. The small but smart MAGLUMI X3 is a small-footprint desktop analyzer having a throughput of 200 t/h, 20 reagent positions, and 72 sample positions to target for small- and mid-size laboratories and hospitals.

The most cost-effective analyzer and the newest member of the X-series - MAGLUMI X6 - with a higher throughput of up to 450 T/h offers up to 30 reagent positions and up to 112 sample positions, or up to 412 when integrated with a sample-storage module. The fastest analyzer in the X series - MAGLUMI X8 - is the most powerful CLIA analyzer that offers a super-high throughput of 600 t/h while ensuring the highest level of precision. It offers 42 reagent positions and 300 sample positions. MAGLUMI X8 can be integrated with the Biossays C8 to create the Biolumi CX8 biochemical and immunological integrated analyzer.

Aided by the incredible X Tech, the MAGLUMI X series CLIA analyzers possess even more powerful capabilities such as patented pipetting technology, accurate incubation technology, stable and precise measuring technology, multiple expansion solutions, and user-friendly and high-efficiency loading design. These latest high-end features help the MAGLUMI X series CLIA analyzers to provide better immunology diagnostic capabilities for laboratories and hospitals.

Related Links:

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
POCT Fluorescent Immunoassay Analyzer
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article


Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more


view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.